TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).

Advanced Healthcare Materials
Huan HouZhengqiang Yuan

Abstract

Although mesenchymal stem cells (MSCs) can be engineered to deliver the TNF-related apoptosis-inducing ligand (TRAIL) as an effective anticancer therapy, the clinical application is hampered by the costly manufacturing of therapeutic MSCs. Therefore, it is needed to find an alternative cell-free therapy. In this study, TRAIL-armed endoplasmic reticulum (ER)-derived nanosomes (ERN-T) are successfully prepared with an average size of 70.6 nm in diameter from TRAIL transduced MSCs. It is demonstrated that the ERN-T is significantly more efficient for cancer cell killing than the soluble recombinant TRAIL (rTRAIL). AZD5582 is an antagonist of the inhibitors of apoptosis proteins (IAPs), and its combination with ERN-T induces strikingly enhanced apoptosis in cancerous but not normal cells. AZD5582 sensitizes resistant cancer cells to TRAIL through concomitant downregulation of IAP members like XIAP and the Bcl2 family member Mcl-1. Intravenously infused ERN-Ts accumulate in tumors for over 48 h indicating good tumor tropism and retention. The combination of ERN-T and AZD5582 drastically promotes therapeutic efficacy comparing with the cotreatment by rTRAIL and AZD5582 in a subcutaneous MDA-MB-231 xenograft tumor model. The data thus...Continue Reading

References

Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Mar 21, 2001·Cell·S J RiedlG S Salvesen
Jun 4, 2002·Nature Reviews. Molecular Cell Biology·Guy S Salvesen, Colin S Duckett
Dec 18, 2008·European Journal of Immunology·Vassiliki SofraSuling Li
Oct 6, 2009·The Journal of Biological Chemistry·Isabella ParoliniStefano Fais
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid S Mendelson
Jul 24, 2010·Nature Reviews. Cancer·Mads Gyrd-Hansen, Pascal Meier
Nov 11, 2010·British Journal of Cancer·M R LoebingerS M Janes
Sep 14, 2012·Frontiers in Physiology·Serena Rubina BaglioNicola Baldini
May 4, 2013·British Journal of Pharmacology·O MicheauF Dufour
Mar 14, 2017·Progress in Biophysics and Molecular Biology·Kumar Selvarajoo
Mar 23, 2017·Journal of Extracellular Vesicles·ZhengQiang YuanSam M Janes
Apr 21, 2017·Apoptosis : an International Journal on Programmed Cell Death·Rama RathoreDietrich Büsselberg
May 26, 2017·Nature Reviews. Cancer·Silvia von KarstedtHenning Walczak
Jun 7, 2017·Oncology Reviews·George E NaoumWaleed O Arafat
Sep 26, 2017·Advanced Healthcare Materials·Francesca BiscagliaMoreno Meneghetti
Aug 1, 2018·International Journal of Molecular Sciences·Kamal Shaik FakiruddinSyahril Abdullah
Feb 12, 2019·Scientific Reports·Carlotta SpanoMassimo Dominici
Sep 29, 2019·Critical Reviews in Oncology/hematology·Sonia How Ming WongSiew Ching Ngai
Nov 23, 2019·Theranostics·Sierra WalkerJoy Wolfram
Feb 11, 2020·Advances in Experimental Medicine and Biology·Huda AtiyaLan Coffman
Sep 19, 2020·Journal of Extracellular Vesicles·Zakia BelhadjQiang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis